Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba

A Double Blind Randomized Trial, Placebo-controled of 0.0003% Calcitriol Ointment Versus 0.1% Tacrolimus Ointment in the Treatment of Pityriasis Alba

Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, trend to relapse and aesthetic impact. Currently, no treatment is widely accepted. The objective is to assess the calcitriol and tacrolimus ointment efficacy in the treatment of PA compared with petrolatum. Twenty lesions on the face greater than 3 cm, in individuals of phototype IV-V, aged 3-18 years are going to be randomly assigned to receive petrolatum, calcitriol, and tacrolimus twice daily. No photoprotection is going to be indicated, and hygienic habits will not be modified. Patients will be evaluated at baseline and for 9 weeks, by means of Transepidermal Water Loss (TEWL), colorimetry, clinically and by photography control.

Study Overview

• Status: Completed
• Conditions: Pityriasis Alba
• Intervention / Treatment: Drug: Calcitriol; Drug: Tacrolimus; Drug: Petrolatum

Detailed Description

Pityriasis alba (PA) is a benign inflammatory dermatosis affecting about 5% of infantile population, frequently seen in tropical areas of the world. This entity has received many synonymous such as chronic impetigo and erythema streptogenes, but its actual name was given from Hazen. PA is also considered a minor criterion for the diagnosis of atopic dermatitis. It is characterized by hypopigmented, irregular plaques with well-defined borders, covered by fine scales; it affects mainly face, limbs and occasionally thorax.

Its etiology is still unknown, although infectious mechanisms and vitamin and minerals deficiencies have been implicated, a causal relationship has not been recognized. However, excessive and unprotected sun exposure is considered the most important causal factor involved. However, studies from stratum corneum from of PA lesions have described defects in hygroscopicity and water-holding capacity detectable by water sorption-desorption test, this suggests that the condition is similar to a dermatitic change and its hypopigmentation may be consequence of a postinflammatory mechanism.

The study population will include at least 20 lesions in individuals with phototype IV-V, affected symmetrically by PA on the face. Their selected age will be less than 18 years. Patients with other dermatoses, including atopic dermatitis, use of any systemic or topical medication during the past 4 weeks will be excluded. Informed consent was obtained from the parents and children before entering the study, which was approved by the local ethical committee (Institutional Review Board).

Patients will be randomly assigned in a double-blind manner to receive on the lesions 0.0003% calcitriol (Galderma, France), 0.1% tacrolimus (Astellas, Pharma, USA), and petrolatum (Aquaphor ointment)in all of them. All subjects were instructed to apply the treatment twice daily. Sunscreen will not be indicated, and hygienic habits are not being changed. Hypopigmented areas are going to be initially evaluated and supervised at 3, 6 and 9 weeks. Digital photographic registration(frontal, right, and left views) with an SLR Fuji FinepixS1pro camera will be taken and analysed by ImageJ software to quantify the reduction area of the plaques. The methods of assessment involve clinical evaluation by investigators, an independent observer, and by the transepidermal water loss (TEWL) with an evaporimeter (Dermalab, Cortex Technology, Denmark), and pigmentary changes using a colorimeter (Chromameter CR-300, Minolta, Osaka, Japan). Water loss will be recorded on each plaque for 60 seconds, as well as the L* (luminosity) and a* (erythema) axis. All adverse effects will be recorded. Statistical analysis was performed using T student, the level of significance was set at 5%. And clinical evaluation will be analysed by means of chi square tests.

• Study Type: Interventional
• Enrollment (Actual): 39
• Phase: Phase 4

Contacts and Locations

Study Locations

• Mexico
  • San Luis Potosi, Mexico, 78210
    • Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto"

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of Pityriasis alba with well defined lesions greater than 3 cm2.

Exclusion Criteria:

• Diagnosis of Atopic Dermatitis
• Skin disorders other than Pityriasis alba
• Systemic disorders
• Treatment during the last 8 weeks for this condition

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Calcitriol; Repigmentation treatment for the relief of hypopigmented pityriasis alba lesions	Drug: Calcitriol; 0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.; Other Names: Silkis; Topical Vitamin D analogs
Active Comparator: Tacrolimus; Treatment for the relief of hypopigmented pityriasis alba lesions	Drug: Tacrolimus; 0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.; Other Names: Protopic; FK506 ointment
Placebo Comparator: Petrolatum; Petrolatum treatment for the relief of hypopigmented pityriasis alba lesions	Drug: Petrolatum; Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.; Other Names: Vaseline; Acuaphore

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Repigmentation of PA lesions measured by colorimetry	Quantification of the repigmentation of lesions by means of the L axis of the CIE system. 0 is pure white, 100 y total dark.	9 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in transepidermal water loss of PA lesions	Quantification of water loss measured by a evaporimeter in grams per squared meter per hour. Is an indirect measure of stratum corneum integrity.	6 weeks
Investigator's repigmentation improvement	Clinical improvement is assessed by means of digital photographic registration (frontal, right, and left views). An independent observer clinically graded the global improvement as poor (0-25%), mild (26-50%), good (51-75%), and excellent (>75%).	9 weeks
Reduction of the affected area by image analysis software	ImageJ software will be used to measure the lesion reduction area after treatments	9 weeks

Collaborators and Investigators

• Sponsor: Universidad Autonoma de San Luis Potosí
• Collaborators: Hospital Central "Dr. Ignacio Morones Prieto"
• Investigators: Study Chair: Juan P Castanedo-Cazares, MD, Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto". San Luis Potosi, México

Study record dates

Study Major Dates

• Study Start: January 1, 2008
• Primary Completion (Actual): August 1, 2010
• Study Completion (Actual): January 1, 2011

Study Registration Dates

• First Submitted: June 30, 2011
• First Submitted That Met QC Criteria: July 5, 2011
• First Posted (Estimate): July 6, 2011

Study Record Updates

• Last Update Posted (Estimate): September 26, 2012
• Last Update Submitted That Met QC Criteria: September 25, 2012
• Last Verified: September 1, 2012

More Information

Terms related to this study

• Keywords: Tacrolimus; Pityriasis alba; Calcitriol; Petrolatum
• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Dermatitis; Scalp Dermatoses; Dandruff; Pityriasis; Pityriasis Rosea; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Immunosuppressive Agents; Immunologic Factors; Dermatologic Agents; Micronutrients; Membrane Transport Modulators; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Emollients; Vasoconstrictor Agents; Calcineurin Inhibitors; Calcium Channel Agonists; Vitamin D; Tacrolimus; Calcitriol; Petrolatum
• Other Study ID Numbers: PA-CALTAC